Myriad Genetics, Inc.
MYGN
Market Cap$358.55M
Close$
$-8.81
314.4% downside
Current Fair Value
314.4% downsideOvervalued by 314.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $358.55 Million |
|---|---|
| Enterprise Value | $405.95 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-3.18 |
| Beta | 2.02 |
| Outstanding Shares | 90,900,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -3.05 |
|---|---|
| PEG | 4.77 |
| Price to Sales | 0.46 |
| Price to Book Ratio | 0.51 |
| Enterprise Value to Revenue | 0.49 |
| Enterprise Value to EBIT | -3.66 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.36 |
| Debt to Equity | 0.2 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Myriad Genetics, Inc.
2,600 employees
CEO: R. Bryan Riggsbee Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing disease, accura...